SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 22, 1999 AVANT IMMUNOTHERAPEUTICS, INC. (Exact Name of Registrant as specified in its charter) Delaware 0-15006 13-3191702 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 119 Fourth Avenue, Needham, MA 02494 (Address of principal executive offices and zip code) (781) 433-0771 (Registrant's telephone number, including area code) ITEM 5. OTHER EVENTS On September 22, 1999, Avant Immunotherapeutics, Inc. (the "Company") issued the press release (attached as Exhibit 99.1 to this Current Report on Form 8-K) announcing the private offering of unregistered securities of the Company. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits EXHIBIT NO. DESCRIPTION 99.1 Press release announcing the private offering of unregistered securities of the Company. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 20, 1999 AVANT IMMUNOTHERAPEUTICS, INC. By: /s/ Una S. Ryan -------------------------- Una S. Ryan, Ph.D. President, Chief Executive Officer and Assistant Secretary